CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?

The success of chimeric antigen receptor T-cell (CAR-T) therapies in the treatment of hematologic malignancies has led to the investigation of their potential in the treatment of solid tumors, including ovarian cancer. While the immunosuppressive microenvironment of ovarian cancer has been a barrier...

Full description

Saved in:
Bibliographic Details
Published inDiagnostics (Basel) Vol. 14; no. 8; p. 819
Main Authors Cutri-French, Clare, Nasioudis, Dimitrios, George, Erin, Tanyi, Janos L.
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.04.2024
Subjects
Antigens
B cells
Cancer therapies
CAR-T therapy
Care and treatment
Cell adhesion & migration
Cell division
Clinical trials
Cytokines
Dendritic cells
Design
Development and progression
Endometrium
Epidermal growth factor
Folic acid
Glycoproteins
Health aspects
Immunotherapy
Kidneys
Kinases
Lungs
Lymphocytes
mesothelin
Mesothelioma
Metastasis
Ovarian cancer
Pancreas
Proteins
Stem cells
T cells
target antigens
Tumors
Uterus
Vitamin B
ovarian cancer
target antigens
CAR-T therapy
mesothelin
Online AccessGet full text

Cover

More Information
Summary:The success of chimeric antigen receptor T-cell (CAR-T) therapies in the treatment of hematologic malignancies has led to the investigation of their potential in the treatment of solid tumors, including ovarian cancer. While the immunosuppressive microenvironment of ovarian cancer has been a barrier in their implementation, several early phase clinical trials are currently evaluating CAR-T cell therapies targeting mesothelin, folate receptor a, HER2, MUC16, and B7H3. Ongoing challenges include cytokine-associated and “on-target, off-tumor” toxicities, while most common adverse events include cytokine release syndrome, hemophagocytic lymphohistiocytosis/macrophage activation-like syndrome (HLH/MAS), and neurotoxicity. In the present review, we summarize the current status of CAR-T therapy in ovarian cancer and discuss future directions.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2075-4418
2075-4418
DOI:10.3390/diagnostics14080819